Scribe Therapeutics Inc.(SCTX)

Biotechnology · Alameda, CA

$16.33+0.12 (+0.74%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T20:38:09.356Z.

Stored calculation inputs

Calculation as of: 2026-10-06T20:38:09.356Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 264,252,223
Total debt: N/A
Cash: N/A
TTM free cash flow: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

SCTX EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

SCTX Competitors' EV/FCF Ratio

SCTX

Scribe Therapeutics Inc.

Current

Market Cap

$264.25M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TLSI

TriSalus Life Sciences, Inc.

vs SCTX

Market Cap

$262.92M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EYPT

EyePoint Pharmaceuticals, Inc.

vs SCTX

Market Cap

$265.78M

EV/FCF Ratio

N/A

TTM Avg

48.59x

3Y Avg

48.59x

5Y Avg

48.59x

SABS

SAB Biotherapeutics, Inc.

vs SCTX

Market Cap

$266.59M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

FATE

Fate Therapeutics, Inc.

vs SCTX

Market Cap

$266.92M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IKT

Inhibikase Therapeutics, Inc.

vs SCTX

Market Cap

$261.43M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XFOR

X4 Pharmaceuticals, Inc.

vs SCTX

Market Cap

$261.27M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OSUR

OraSure Technologies, Inc.

vs SCTX

Market Cap

$259.56M

EV/FCF Ratio

N/A

TTM Avg

0.65x

3Y Avg

2.46x

5Y Avg

493.92x

TMCI

Treace Medical Concepts, Inc.

vs SCTX

Market Cap

$259.49M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EPRX

Eupraxia Pharmaceuticals Inc.

vs SCTX

Market Cap

$259.14M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Scribe Therapeutics Inc. (SCTX)	$264.25M	N/A	N/A	N/A	N/A
TriSalus Life Sciences, Inc. (TLSI)vs ›	$262.92M	N/A	N/A	N/A	N/A
EyePoint Pharmaceuticals, Inc. (EYPT)vs ›	$265.78M	N/A	48.59x	48.59x	48.59x
SAB Biotherapeutics, Inc. (SABS)vs ›	$266.59M	N/A	N/A	N/A	N/A
Fate Therapeutics, Inc. (FATE)vs ›	$266.92M	N/A	N/A	N/A	N/A
Inhibikase Therapeutics, Inc. (IKT)vs ›	$261.43M	N/A	N/A	N/A	N/A
X4 Pharmaceuticals, Inc. (XFOR)vs ›	$261.27M	N/A	N/A	N/A	N/A
OraSure Technologies, Inc. (OSUR)vs ›	$259.56M	N/A	0.65x	2.46x	493.92x
Treace Medical Concepts, Inc. (TMCI)vs ›	$259.49M	N/A	N/A	N/A	N/A
Eupraxia Pharmaceuticals Inc. (EPRX)vs ›	$259.14M	N/A	N/A	N/A	N/A

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/FCF Ratio: N/A

SCTX EV/FCF Ratio Metrics

SCTX Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

Related Metrics